RxDoctor Payments DataLook up a doctor →

Gary Yawn, MD

Interventional Cardiology · Hendersonville, TNNPI 1013179860

Payments from drug & device makers

$29,192in general payments, 2019–2025

Across 567 payments — averaging $51.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$12K
  • Boston Scientific$3K
  • Actelion Pharmaceuticals US, Inc.$3K
  • Cardiovascular Systems Inc.$3K
  • Abiomed$2K
  • Johnson & Johnson$1K
  • plus $6K from 37 others

What the payments were for

  • Consulting fees$7,12524%
  • Speaking & faculty fees$1,5005%
  • Travel & lodging$6,93324%
  • Food & beverage$13,59747%
  • Education$360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,192 in reported general payments places this provider in the 75th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$168,901
Medicare patients
578
Services billed
1,663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan18$217,146
EliquisApixaban108$93,397
XareltoRivaroxaban88$86,485
Repatha SureclickEvolocumab113$70,606
JardianceEmpagliflozin70$57,171
EntrestoSacubitril/Valsartan51$49,744
OzempicSemaglutide25$23,206
WegovySemaglutide14$19,295
Ranolazine ErRanolazine146$11,570
BrilintaTicagrelor13$8,006
Icosapent Ethyl22$5,743
NexlizetBempedoic Acid/Ezetimibe12$5,399
VascepaIcosapent Ethyl11$4,293
Atorvastatin Calcium390$4,268
Rosuvastatin Calcium247$3,392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$2,902$217,14618 claims
PfizerEliquis$293$93,397108 claims
Johnson & JohnsonXarelto$1,014$86,48588 claims
Boehringer IngelheimJardiance$176$57,17170 claims
NovartisEntresto$183$49,74451 claims
Novo NordiskOzempic, Wegovy$63$42,50139 claims
AstraZenecaBrilinta$313$8,00613 claims
Esperion Therapeutics, Inc.Nexlizet$39$5,39912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Hendersonville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →